Member Info for RoyRoy

There are many reasons why an investor might sell:

1. Stop loss kicks in
2. Require money for a bill (e.g. urgent medical)
3. Need to cover losses elswhere.
4. Over exposed in one stock and need to diversify.
5. etc etc

It maybe that they have no alternative. Count yourself lucky that you don't have to sell at such an unfortunate time. Or that a forgotten stop loss hasnt ruined your plans for early retirement...

On your second point, No there has not been a postponement ...
"...the Company will release interim results for the six months ended 30 June 2020 at 7.00 a.m. on 28 October 2020 and provide a live presentation of the results at 1.00 p.m..."
https://www.lse.co.uk/rns/ITX/notice-of-interim-results-7wxo99ubaggbnim.html

Unlikely seeing as its so close to the interims.

Furthermore I don't think it matters. There is ample information out there already to gain insights.

Full results 2019, unaudited H1's, recent proactive interviews (ie https://www.youtube.com/watch?v=xM4o0GBt9Xs), the last few pages of this BB, etc etc

What more are you after?

I think the chances of them looking for cash at this stage are very slim.

John Shaw has said repeatedly in interviews and within RNS that ITX have enough cash til at least the end of 2021.
They have a production facility that is capable of 15x what they currently produce with very little additional investment.
They are at the stage where they want to grow the existing product orders. They have many repeating orders and they want to maximise the revenue from these relationships.
However, if they were to ask for cash at this stage, I would imagine it would have to be for a contract with monumental order volume and I cannot imagine the share price dropping if this was the case.

As for it being positive or negative... read the recent 2019 Full results and the 2020 H1 unaudited for a flavour of what this one will taste like...

Surely you're not expecting to be taken seriously if you're going declare "The only positive part is..."!

There are many positive things coming out of ITX, eg, the RNS only 2 weeks ago states...

"Financial results for 2019 show increased demand for the Company's products, significant cost savings from the restructuring of operations in 2018...
· Total revenues increased...
· Gross profits increased ...
· Net losses decreased...
· Losses before interest, tax and non-cash items decreased ..."

For sure, this relatively new AIM company has a way to go before it turns a profit but it's rapidly heading in that direction. Please someone correct me if I'm wrong...

I don't think there will be any real surprises...
Increase in revenues ~60%
Decrease in Operating Loss ~50%
= A solid step forward in the path to profitability and a quote from John Shaw talking about "acceleration in our revenue growth" and "commercial momentum continuing to build".

I expect this RNS has been priced in and there will be some who see if as a reason to sell.
I suspect the next trading update (2020 Half year) has not and will be good reason to buy!

Yes, good but ... "Published: 2020-07-13" ... so not new(s).

This is an AIM company which has a strategy to acheive profitability.

"The net proceeds from the fundraise are expected to provide sufficient funding for the Company until at least the end of 2021, during which the Company expects to make significant progress towards its medium-term plan to achieve break-even profitability."
- RNS | H1 2020 Trading Update

Interesting article on how Coronavirus has "hit the industry hard".

https://www.theguardian.com/world/2020/aug/03/growers-and-producers-at-odds-in-france-champagne-wars-coronavirus

Today's RNS...
"Aggregate of Standard Life Aberdeen plc affiliated investment management entities..." takes 7.5%.
Would I be wrong is seeing that as a signal to buy...?

Although I'm inexperienced in both trading and pharma, it seems to me that Faron might be playing it well.
They donate a relatively small amount of Traumakine, a drug not yet released to market, to the Covid trials knowing that other companies will be supplying interferon beta-1a. Faron will not only benefit from the research data released regarding Traumakine but also that on interferon beta-1a as a treament for Covid conditions.
They also know that Rebif is delivery by subcutaneous (under the skin) injection and not intravenous (into a vien) hence why they released their paper differentiating between the 2 delivery methods.
I'd say, they know exactly what they are doing. Time will tell.

Sky news article quote...

Dr Hill said some results of the drug studies will be announced at an international conference next week, adding: "I can't tell you anything right now. But it's definitely time to watch this space and think about alternatives too."

"...and we think that's going to lead to a very strong second half."
John Shaw sounding confident [4:43]

Looks interesting but crop spraying with polymers is still on a basic level crop spraying with "plastics".
Furthermore, there's no mention within the article whether or not these synthetic acrylate polymers are safe for human consumption.
Lastly, "this early research is unlikely to result in farmers having polymer sprays to fight fungal disease for some time."...
No need to worry quite yet.

Am i reading this right...

"Placing of a minimum of 101,770,000 Placing Share"
Total new shares = 101,770,000

"Certain of the Directors, and senior management, intend to subscribe for an aggregate of 18,259,090 Second Placing Shares"
Of which directors etc want 18,259,090, roughly a fifth.

What a vote of confidence in the future of the company they run.

Currently.... Shares in Issue: 3,071m. This seems like a large number, no? Way more than say Faron with Shares in Issue: 47m. Does the number of shares in issue have any meaning in terms of stock value?
*At the moment just looking to start investing